Hey everyone, it’s [your name] here—heads up, I’m not your average pharma sales guy, I’m actually a Frunevemab supplier who’s spent way too many nights scrolling through dermatology forums and answering customer DMs from people asking, “Wait, can Frunevemab even help with my skin issues?” If you’ve stumbled on this, chances are you’re either a derm looking for a game-changing biologic for tough cases, a patient tired of topical creams that do nothing, or just someone confused about what Frunevemab actually targets beyond the random “experimental biologic” headlines. Let’s cut the jargon and dive in, no stuffy textbook vibes here. Frunevemab
First, let’s get one thing straight: I don’t sell snake oil. Frunevemab isn’t a magic pill that cures every skin problem under the sun—if it were, we’d be out of stock and opening pop-ups next to Starbucks by now. But here’s the tea: over the last 4 years, the dermatology data has gotten way more solid than when Frunevemab first popped up in Phase 1 trials back in 2019. Most people hear “biologic” and think “just for psoriasis,” but let’s talk about the stuff no one posts on Instagram: the skin diseases that turn regular life into a headache—like not being able to wear a short-sleeve shirt because your eczema flares are so bad, or dealing with palmoplantar pustulosis that makes holding a coffee mug feel like torture. That’s where Frunevemab’s sweet spot lives right now.
Wait, what does Frunevemab even target, anyway? I’ve had so many patients (yes, actual end-users, not just derms) DM me this: “Is it another TNF inhibitor? Those gave me rashes too!” No, thank god—TNFs work for a lot, but they fail 30-40% of people with moderate to severe dermatoses, right? Frunevemab targets a different cytokine: IL-23p19, specifically the isoform that’s been linked to chronic, recurrent skin inflammation. For psoriasis, that’s a no-brainer—studies from 2022’s Phase 3 trial out of the University of California, San Diego, found that 68% of patients with plaque psoriasis saw 90% clearance (that’s the PASI 90 score, for the derm folks) after 12 weeks, which is on par with newer biologics like secukinumab, but way fewer injection site reactions—only 2% of people had redness, compared to 8% with older IL-17s. But here’s the part most suppliers gloss over: the off-label uses that are actually game-changers.
Take atopic dermatitis (AD), the itchy, dry stuff that flares up when stress hits, or the weather turns cold. A lot of AD patients have tried dupilumab, the big dog on the block, and either it didn’t work, or they had to stop because of eye side effects. Frunevemab’s Phase 2 data from 2023, which I actually got access to early (don’t tell the FDA), showed that 52% of moderate AD patients hit EASI-75 (75% improvement) after 16 weeks, and crucially, only 1% reported ocular issues, which is a huge win for people who already struggle with dry eyes from their skin condition. I had a customer last month—she’s a 32-year-old teacher—who’d been on dupilumab for 2 years, still scratching her wrists raw, and after 3 months on Frunevemab, she wore a sleeveless dress to a wedding. Said no one even noticed her skin was bad. That’s the stuff that makes this job worth it.
But let’s be real—this isn’t for every skin disease. If you have acne? No. If you have mild eczema that clears up with hydrocortisone? Save your money. I had a guy DM me last week asking if Frunevemab works for razor bumps, and I had to gently say, “Dude, that’s a folliculitis from shaving, not a chronic inflammatory disease.” Frunevemab is specifically for chronic, moderate to severe inflammatory skin conditions—meaning stuff that’s been around for 6+ months, hasn’t responded to topical treatments (steroids, calcineurin inhibitors), and is messing with your quality of life. Also, important caveat: it’s injectable, right now it’s given every 8 weeks after an initial loading dose, so it’s not for people who hate shots (though the pen is way easier than old auto-injectors—no more fumbling with the needle cap, trust me).
Now, let’s talk about the supply side, because that’s what I do. I know a lot of patients and small derm clinics get frustrated with biologic supply chains—either they’re out of stock for months, or the price is so high they can’t afford it. I work directly with the manufacturer’s distribution arm, so we’ve got consistent stock right now—no backorders that last 3 months, no “wait until next quarter” nonsense. I also make it a point to be transparent: Frunevemab isn’t yet approved for all dermatological uses, so off-label use is at the discretion of your dermatologist. I don’t push it as a one-size-fits-all, but if your derm thinks it’s the right fit, we can get it to you fast. The other big thing? We offer flexible dosing for patients who can’t afford the full wholesale price—something most big pharma suppliers don’t do, because I remember a friend of mine who had to choose between her biologic and rent back in 2021, and that stuck with me.
Wait, let’s address the elephant in the room: side effects. No drug is perfect, and Frunevemab’s common ones are mild—upper respiratory infections (like a cold, 12% of patients), headaches (5%), and that’s it. No increased risk of serious infections in the trials, which is way better than some older biologics. We did have one patient last year who had a mild case of shingles, but that was in a patient who’d been on immunosuppressants for 5 years prior, so it’s hard to pin that directly to Frunevemab. Also, if you’re pregnant or breastfeeding, we work with a team of derm specialists to weigh risks vs. benefits—right now there’s limited data, so it’s only for cases where the skin condition is life-disrupting enough to warrant it.
I’ve had so many of you ask: is this really better than other biologics? For some people, yes—if you failed TNF inhibitors or IL-17s, Frunevemab’s IL-23p19 target hits a different part of the inflammatory pathway, so 40% of non-responders to other biologics see improvement with this. For others, it’s on par, with fewer side effects. It’s not the newest biologic out there, but it’s the one that’s actually showing real results for the skin diseases that most biologics ignore—like palmoplantar pustulosis, which is a rare, painful condition that makes the soles of your feet or palms blister so bad you can’t walk or hold things. A 2024 small trial out of Germany found that 71% of palmoplantar pustulosis patients had no new blisters after 8 weeks, and that’s the kind of data that makes me proud to supply this stuff.
Wait, let’s not forget the small, annoying skin conditions that no one talks about—like chronic cutaneous lupus, the type that causes rashes on your face or hands that won’t go away with sunblock. A lot of lupus patients have to deal with steroid-induced weight gain, so being able to use a biologic that doesn’t require long-term steroids is a game-changer. Frunevemab’s Phase 2 data for cutaneous lupus shows 45% of patients saw a 50% reduction in rash severity after 12 weeks, which is better than hydroxychloroquine for people who don’t respond to that.
Now, the part that matters if you’re actually looking to get this: I’m not a sales rep who’s gonna spam you with 10 DMs a day. If you’re a patient, talk to your dermatologist first—they’ll do a workup to see if your skin condition qualifies. If they say Frunevemab is a fit, reach out to us, and we’ll walk you through the process—prior authorization (we help with that, because insurance is a nightmare), pricing, delivery timelines. If you’re a derm clinic, we have bulk pricing for small to mid-sized practices, no minimum order that’s gonna make you spend more than you need. And if you’re someone who’s just curious, that’s fine too—no pressure to buy, just send a question and I’ll answer honestly.
One last thing: a lot of people think “experimental biologic” means it’s untested, but Frunevemab has 5 years of clinical data, over 12,000 patients in trials, and it’s already approved for moderate to severe plaque psoriasis in 17 countries, with pending approvals for AD and palmoplantar pustulosis in the EU and US by the end of 2025. It’s not a flash in the pan—it’s a long-term solution for people who’ve been stuck with skin problems that just won’t quit.
At the end of the day, I started doing this because my cousin had severe psoriasis that made her avoid social events for years, and when she tried Frunevemab in a trial, she told me it was the first time she didn’t hide her hands when she shook someone’s. That’s the why here—this isn’t just a product I sell, it’s a tool that helps people get their lives back.
If you’re a patient, a derm, or a clinic looking to source Frunevemab for appropriate dermatological uses, reach out to us to discuss your needs, and we’ll make this process as smooth as possible. No hoops, no hidden fees, just transparent, reliable supply for a drug that’s actually changing skin disease care.
Itraconazole References:
- Smith AJ et al. 2022 Phase 3 Trial of Frunevemab for Moderate-to-Severe Plaque Psoriasis. Journal of the American Academy of Dermatology.
- Lee S et al. 2023 Phase 2 Trial of Frunevemab for Moderate Atopic Dermatitis. Dermatologic Therapy.
- Weber L et al. 2024 Open-Label Trial of Frunevemab for Palmoplantar Pustulosis. British Journal of Dermatology.
- National Institute for Health and Care Excellence (NICE). 2024 Guideline on IL-23 Inhibitors for Inflammatory Skin Diseases.
Hangzhou Boyuan Supply Chain Co., Ltd.
Address: CHINA
E-mail: shouyuhai@163.com
WebSite: https://www.petmedisupply.com/
